Prelude Capital Management, LLC Alaunos Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.39 Billion
- Q2 2024
A detailed history of Prelude Capital Management, LLC transactions in Alaunos Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 800 shares of TCRT stock, worth $1,664. This represents 0.0% of its overall portfolio holdings.
Number of Shares
800Holding current value
$1,664% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding TCRT
# of Institutions
5Shares Held
92.6KCall Options Held
0Put Options Held
0-
Gamble Jones Investment Counsel61KShares$126,8800.0% of portfolio
-
Altium Wealth Management LLC15KShares$31,2000.0% of portfolio
-
Sawtooth Solutions, LLC14.3KShares$29,6400.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.1KShares$4,3680.0% of portfolio
-
Trustcore Financial Services, LLC250Shares$5200.0% of portfolio
About Alaunos Therapeutics, Inc.
- Ticker TCRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,182,000
- Market Cap $450M
- Description
- Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...